loading
Avidity Biosciences Inc stock is traded at $34.56, with a volume of 3.34M. It is down -4.71% in the last 24 hours and up +19.05% over the past month. Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$36.27
Open:
$36.5
24h Volume:
3.34M
Relative Volume:
2.01
Market Cap:
$4.17B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-11.96
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
+1.59%
1M Performance:
+19.05%
6M Performance:
+7.73%
1Y Performance:
-28.21%
1-Day Range:
Value
$34.53
$36.79
1-Week Range:
Value
$32.72
$37.59
52-Week Range:
Value
$21.51
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Name
Avidity Biosciences Inc
Name
Phone
858-401-7900
Name
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Employee
391
Name
Twitter
Name
Next Earnings Date
2024-12-07
Name
Latest SEC Filings
Name
RNA's Discussions on Twitter

Compare RNA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RNA
Avidity Biosciences Inc
34.56 4.37B 10.12M -280.49M -188.51M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-10-25 Resumed Goldman Buy
Jun-24-25 Initiated Bernstein Outperform
Jun-17-25 Initiated Wolfe Research Outperform
Jun-11-25 Initiated Raymond James Strong Buy
Mar-13-25 Initiated Citigroup Buy
Mar-12-25 Initiated BMO Capital Markets Outperform
Mar-07-25 Initiated Scotiabank Sector Outperform
Dec-20-24 Initiated H.C. Wainwright Buy
Nov-26-24 Initiated RBC Capital Mkts Outperform
Sep-24-24 Initiated Goldman Buy
Aug-28-24 Initiated Barclays Overweight
May-03-24 Initiated BofA Securities Buy
Mar-14-24 Initiated Cantor Fitzgerald Overweight
May-22-23 Upgrade Evercore ISI In-line → Outperform
Mar-31-23 Downgrade Evercore ISI Outperform → In-line
Jul-20-22 Initiated Chardan Capital Markets Buy
Jul-12-22 Initiated Raymond James Strong Buy
Sep-07-21 Initiated Evercore ISI Outperform
Jun-17-21 Initiated Needham Buy
Apr-26-21 Resumed Credit Suisse Outperform
Jul-07-20 Initiated Cowen Outperform
Jul-07-20 Initiated Credit Suisse Outperform
Jul-07-20 Initiated SVB Leerink Outperform
Jul-07-20 Initiated Wells Fargo Overweight
View All

Avidity Biosciences Inc Stock (RNA) Latest News

pulisher
Jul 28, 2025

Trendline Breach Raises Concern for Avidity Biosciences Inc. InvestorsStable Entry High Return Opportunities in Focus - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Avidity Biosciences and the Potential for First-in-Class DM1 Therapy - AInvest

Jul 28, 2025
pulisher
Jul 28, 2025

Avidity completes enrollment for phase 3 trial of DM1 treatment By Investing.com - Investing.com South Africa

Jul 28, 2025
pulisher
Jul 28, 2025

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission - PR Newswire

Jul 28, 2025
pulisher
Jul 28, 2025

What is the dividend policy of Avidity Biosciences Inc. stockDiscover stocks with explosive upside potential - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about Avidity Biosciences Inc.Capitalize on fast-growing stocks today - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How volatile is Avidity Biosciences Inc. stock compared to the marketMaximize your returns with portfolio optimization - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Should I hold or sell Avidity Biosciences Inc. stock in 2025Get alerts on the hottest market movers - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Avidity Biosciences Inc. generate profit in a changing economyMassive stock growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is it the right time to buy Avidity Biosciences Inc. stockExpert guidance for superior capital growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What institutional investors are buying Avidity Biosciences Inc. stockHigh-margin investment plays - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What makes Avidity Biosciences Inc. stock price move sharplyUnlock exclusive stock analysis for investors - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why is Avidity Biosciences Inc. stock attracting strong analyst attentionExtraordinary earning power - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Avidity Biosciences Inc. in the next 12 monthsDiscover stocks with superior performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Avidity (RNA) Jumps 9.2% on Drug Candidate’s Breakthrough Therapy Designation - Insider Monkey

Jul 26, 2025
pulisher
Jul 25, 2025

Avidity Biosciences shares climb after FDA grants Breakthrough Therapy designation - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Is Avidity Biosciences Inc. a good long term investmentFree Stock Market Trend Analysis - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Avidity’s Stock Surge: Time to Act? - timothysykes.com

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Avidity Biosciences Inc. stock priceFree Wealth Planning Blueprint - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

How Avidity Biosciences Inc. stock reacts to Fed policy changesFree Smart Trading Workshop - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Avidity Biosciences shares rise 1.80% premarket after receiving FDA Breakthrough Therapy designation for DMD treatment. - AInvest

Jul 24, 2025
pulisher
Jul 23, 2025

Avidity Biosciences Gains FDA Breakthrough Therapy Designation - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Why Avidity Biosciences Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - beatles.ru

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity gets FDA breakthrough therapy status for DMD treatment - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

FDA grants breakthrough therapy status to Avidity’s DMD drug By Investing.com - Investing.com Canada

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status - Investing.com

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - ETX View

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com

Jul 22, 2025

Avidity Biosciences Inc Stock (RNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
Cap:     |  Volume (24h):